Clinical Trial Update: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas [Phase 2]

View source ↗

Summary

Phase 2 study of LN-145 (LN-145-S1) in relapsed or refractory ovarian cancer, triple-negative breast cancer, anaplastic thyroid cancer, osteosarcoma, and other …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Dedifferentiated Chondrosarcoma
• Giant Cell Tumor of Bone
• Osteosarcoma
• Ovarian Cancer
• Ovarian Carcinosarcoma
• Soft Tissue Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• LN-145 (autologous tumor-infiltrating lymphocytes)
• LN-145-S1

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING